anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a lipid metabolism regulation agent useful as an agent of regulating free acid in blood, an agent of regulating fat metabolism of fat body, an agent of regulating fat metabolism of liver and food, containing proline and/or threonine. CONSTITUTION:An agent of regulating lipid metabolism containing proline and/or threonine. In production, proline and threonine sold on the market are mixed in a powder state, or dissolved in distilled water and water is distilled away to give the agent. The production is preferably carried out at <= room temperature. The agent of regulating lipid metabolism can be medicated by oral administration, rectum administration and administration through injection and transfusion solution and is applicable for drugs such as an agent of regulating free acid in blood, an agent of regulating fat metabolism of fat body or an agent of regulating fat metabolism of liver and foods such as refreshing drink and nutritive tonic drink. Since solid powder and tablet require time for absorption, preferably the agent is mixed with an additive, made into an aqueous solution and administered, etc.
FIELD: medicine. ^ SUBSTANCE: versions of the bond intended for linkage with the external domain B (ED-B) of a fibronectin are offered. The bond includes an antigen-binding fragment of one-chained antibody L19 and a cysteinum-containing linker for hanging of a radioactive label. Versions of a pharmaceutical composition for diagnostics and treatment of angiogenic diseases on the basis of the specified bond are opened. Application of bond for linkage with radioactive bond is described. The method of reception of bond in eucariotic cells is opened, including in Pichia pastoris and a set for reception is radioactive labelled agents on the basis of bond. ^ EFFECT: high-avid bond accumulation in solid tumours. ^ 23 cl, 4 dwg, 5 tbl, 15 ex
Arteriovenous fistulas (AVFs) are the most common vascular access points for hemodialysis (HD), but they have a high incidence of postoperative dysfunction, mainly due to excessive neointimal hyperplasia (NIH). Our previous studies have revealed a highly conserved LncRNA-LncDACH1 as an important regulator of cardiomyocyte and fibroblast proliferation. Herein, we find that LncDACH1 regulates NIH in AVF in male mice with conditional knockout of smooth muscle cell-specific LncDACH1 and in male mice model of AVF with LncDACH1 overexpression by adeno-associated virus. Mechanistically, silence of LncDACH1 activates p-AKT through promoting the expression of heat shock protein 90 (HSP90) and serine/arginine-rich splicing factor protein kinase 1 (SRPK1). Moreover, LncDACH1 is transcriptionally activated by transcription factor KLF9 that binds directly to the promoter region of the LncDACH1 gene. In this work, during AVF NIH, LncDACH1 is downregulated by KLF9 and promotes NIH through the HSP90/ SRPK1/ AKT signaling axis.
A low-frequency variant of sushi, von Willebrand factor type A, EGF, and pentraxin domain-containing protein 1 (SVEP1) is associated with the risk of coronary artery disease, as determined by a genome-wide association study. SVEP1 induces vascular smooth muscle cell proliferation and an inflammatory phenotype to promote atherosclerosis. In the present study, qRT‒PCR demonstrated that the mRNA expression of SVEP1 was significantly increased in atherosclerotic plaques compared to normal tissues. Bioinformatics revealed that EGR1 was a transcription factor for SVEP1. The results of the luciferase reporter assay, siRNA interference or overexpression assay, mutational analysis and ChIP confirmed that EGR1 positively regulated the transcriptional activity of SVEP1 by directly binding to its promoter. EGR1 promoted human coronary artery smooth muscle cell (HCASMC) proliferation and migration via SVEP1 in response to oxidized low-density lipoprotein (ox-LDL) treatment. Moreover, the expression level of EGR1 was increased in atherosclerotic plaques and showed a strong linear correlation with the expression of SVEP1. Our findings indicated that EGR1 binding to the promoter region drive SVEP1 transcription to promote HCASMC proliferation and migration.
If participants were in a CON group, they did not receive the yoga intervention. Instead, they were encouraged to maintain a normal daily lifestyle monitored by the BPAQ at one-month intervals during the 12-week intervention.
A stable bleached shellac and an improved method for making stable bleached shellac which involves precipitating bleached stable shellac from a pre-shellac solution at a pH of from 5.0 to 6.8, preferably from 5.0 to 6.5, most preferably from 5.0 to 6.0. The stable particulate shellac and the stable shellac solution, have a longer shelf life than conventional shellac. The stable shellac solution is comprised of solubilized particulate shellac in a solvent, most preferably ethanol. The stable particulate shellac and the stable shellac solution have a pH of from 4 up to less than 5 or from 5.0 to 6.8, more preferably from 5.0 to 6.5, even more preferably from 5.0 to 6.3, most preferably from 5.0 to 6.0. Where the de-lipidized bleached, stable shellac solution has a pH of from 5.0 to 6.8, it is characterized in that when it is heated to 100 °F for 6 weeks, the pH drops less than 15 %, more preferably not greater than 13 %, most preferably not greater than 12 %. Where the lipidized, bleached stable shellac solution has a pH of from 5.0 to 6.8, it characterized in that when it is heated to 100 °F for 6 weeks, the pH drops less than 30 %, more preferably not greater than 20 %, most preferably not greater than 18 %. Where the bleached stable shellac solutions are aged whether over time or in simulated conditions, the pH of both the de-lipidized and lipidized bleached stable shellac solutions tend to drop. When aged, lipidized stable shellac alcohol solution having an initial pH up to less than 5.0, is heated for 30 days at 40 °C, the pH tends to drop, to preferably not lower than 3.7, more preferably not lower than 3.8. When aged de-lipidized stable shellac alcohol solution having an initial pH up to less than 5.0 is heated for 30 days at 40 °C, the pH tends to drop, to preferably not lower than 4.2, more preferably not lower than 4,3.
Transdermal nanoemugels for systemic delivery of potent drugs like aromatase inhibitors letrozole and anastrozole are disclosed. The disclosed compositions may include gelling agent, surfactants, cosolvents, and oily components. The process of preparing the nanoemulgels is simple and the formation of nanoemulgels is spontaneous. Penetration enhancers are included in the compositions of the transdermal nanoemugels. The compositions have penetration power with emollient effects to the skin. The transdermal drug delivery system may be applied to skin in a single dose that produces pharmacologically effective blood concentration of the potent drug for one week or up to one month depending on the amount and thickness of the applied nanoemugels in the transdermal matrix patches. 
     The nanoemulgels can be used for topical delivery of NSAID.
Conversations about death and dying present discomfort for both healthcare professionals, patients and their families. These conversations, emotionally laden, pose lasting challenges and impact decision-making. Despite extensive medical training, physicians often lack adequate communication skills for such conversations, leading to frustration and distress. Delivering bad news, particularly in pediatrics, requires managing not only medical intricacies but also emotional impact. Communication skills, crucial for such scenarios, are typically developed over time through observation and practice, yet are often inadequately emphasized in medical training. Our study aimed to assess the impact of communication training on medical students delivering death notifications to simulation parents in pediatric simulation scenarios.
PCT No. PCT/SE94/00291 Sec. 371 Date May 25, 1994 Sec. 102(e) Date May 25, 1994 PCT Filed Mar. 31, 1994 PCT Pub. No. WO94/25039 PCT Pub. Date Nov. 10, 1994Cholestyramine and starch containing, oil-free compositions with excellent organoleptic features are obtained by mixing cholestyramine and grain starch in a weight ratio of 1:1.8 to 2.9 with the addition of grain bran as a filler and optionally an aroma stuff with 10 to 35% by weight of water (calc. on the starting materials) into a homogenous moist mass, forming of the mass through extrusion into a string, whereby the temperature is 105 DEG -180 DEG  C. (measured in the mass in the extrusion head) and the pressure is 30-70 bars (measured in the extrusion head), and subsequently drying at a temperature above 100 DEG  C. to a remaining humidity of </=3.5% by weight, whereby the extruded material before or after the drying is divided into bars or is grinded into a powder.
Of the 30 targeted participants, 18 will be randomized at the first three week dosing period {1mg of melatonin}. The randomization will be single blind to the parent in a 5:1 ratio (15 children will receive melatonin, and 3 children will receive a flavored placebo at the first 3-week period only). After the initial 3-week dose cycle of 1 mg, all children randomized to placebo will begin 3 mg of melatonin and will continue in dose increase (6mg, 9 mg)until they meet the criteria of falling asleep within 30 minutes of bedtime 5/7 nights per week. No child will take more than 9 mg.
All patients will undergo preemptive genotyping prior to their surgical procedure. Pharmacogenomic test results will not be made available to providers (standard of care). Genotyping results will be released to study providers (and patients) at the 6-month unblinding timepoint for patients in the control group.
Heart failure (HF) is manifested by transcriptional and posttranscriptional reprogramming of critical genes. Multiple studies have revealed that microRNAs could translocate into subcellular organelles such as the nucleus to modify gene expression. However, the functional property of subcellular Argonaute2 (AGO2), the core member of the microRNA machinery, has remained elusive in HF. AGO2 was found to be localized in both the cytoplasm and nucleus of cardiomyocytes, and robustly increased in the failing hearts of patients and animal models. We demonstrated that nuclear AGO2 rather than cytosolic AGO2 overexpression by recombinant adeno-associated virus (serotype 9) with cardiomyocyte-specific troponin T promoter exacerbated the cardiac dysfunction in transverse aortic constriction (TAC)-operated mice. Mechanistically, nuclear AGO2 activates the transcription of ANKRD1, encoding ankyrin repeat domain-containing protein 1 (ANKRD1), which also has a dual function in the cytoplasm as part of the I-band of the sarcomere and in the nucleus as a transcriptional cofactor. Overexpression of nuclear ANKRD1 recaptured some key features of cardiac remodeling by inducing pathological MYH7 activation, whereas cytosolic ANKRD1 seemed cardioprotective. For clinical practice, we found ivermectin, an antiparasite drug, and ANPep, an ANKRD1 nuclear location signal mimetic peptide, were able to prevent ANKRD1 nuclear import, resulting in the improvement of cardiac performance in TAC-induced HF.
A method for producing a retrievable hairstyling using shape memory polymers is described. Here a composition is applied to the hair, said composition containing a shape memory polymer P or a macromer M that can be cross-linked to a shape memory polymer, the hair is arranged into a given (permanent) shape and said permanent shape is then fixed by means of chemical cross-linking of the macromer M under the formation of a shape memory polymer and/or under physical cross-linking of the polymer P. The polymer P and the macromer M are formed from block copolymers, each of which comprises at least a first block and at least two additional blocks. The first block is a polyol and is selected from polyethers, dimerdiol and derivatives derived therefrom, as well as from polyesters of dicarboxylic acids with diols. The additional blocks are polyesters of hydroxycarboxylic acids or their lactones. The macromer M possesses cross-linkable regions, as well as thermoplastic regions that are not cross-linkable and, after cross-linking, has a transition temperature of T trans . The polymer P has a hard segment with a first transition temperature T′ trans , which is above room temperature, and a soft segment with a second transition temperature T trans  which is lower than T′ trans .
Trientine maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2. Carboplatin maximum tolerated dose found in MTD Dose Escalation Group. PK testing blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
The schizophrenic subjects will undertake a 3 hour session of cognitive experiments. Tasks will include a battery of psychoacoustic tests, a source monitoring task, an externalization task, a pitch discrimination task and a speech-in-speech task.
The efficacy of zileuton extended-release tablets was evaluated in a randomized, double-blind, parallel-group, placebo-controlled, multicenter trial of 12 weeks duration in patients 12 years of age and older with asthma. The 12-week trial included 199 patients randomized to zileuton extended-release tablets (two 600 mg tablets twice daily) and 198 to placebo. Eighty-three percent of patients were white, 48% were male, and the mean age was 34 years. The mean baseline FEV1 percent predicted was 58.5%.

Assessment of efficacy was based upon forced expiratory volume in one second (FEV1) at 12 weeks. Zileuton extended-release tablets demonstrated a significantly greater improvement in mean change from baseline trough FEV1 at 12 weeks compared to placebo (0.39 L vs. 0.27 L; p=0.021). The mean change from baseline FEV1 over the course of the 12-week study is shown in Figure 1. Secondary endpoints (PEFR and rescue beta-agonist use) were supportive of efficacy.

Examination of gender subgroups did not identify differences in response between men and women. The database was not large enough to assess whether there were differences in response in age or racial subgroups.

Figure 1.

Mean Change from Baseline in Trough FEV1 in

12-Week Clinical Trial in Patients with Asthma.

*p ≤0.050. Endpoint analysis based on last-observation-carried-forward (LOCF) methodology.
Usual care for preschool children identified with overweight and obesity Usual care is performed according to national guidelines that invites all 4-year-olds to a '4-years health visit' including a health conversation. A survey on usual care in the case of identified overweight initial to this study among almost all nurses working at the participating CHCs showed that two thirds of questioned CHS-nurses used to invite families in which the child is identified with overweight for 1 or 2 extra visits outside the usual program. The majority o referred children to a dietician, or to another caregiver. All children invites to their regular 5-yrs health visit.
BACKGROUND: Cambodia is a low-income country in South East Asia with a population of 15.5 million people of whom 4.9 million (38%) are under the age of 16. The causes of childhood blindness in Cambodia have not been investigated since the first survey of schools for the blind done in 2009 by our group. Given the large demographic and economic shifts in Cambodia since 2009 it is important to determine if these causes have changed in order to ensure intervention programmes are appropriately targeted. The purpose of the present study is to investigate the prevalence of causes of childhood blindness at schools for the blind in Cambodia.
METHODS: Students between the ages of 5 and 16 years who were attending schools for the blind in Cambodia were examined by a consultant paediatric ophthalmologist and had clinical photographs taken. Distance visual acuity was measured using a logMAR tumbling E chart and the WHO definitions of blindness and severe visual impairment were used. The examining ophthalmologist recorded the anatomical site and aetiology of vision loss using the WHO Prevention of Blindness eye examination record for children. Collected data were compared to a previous survey from 2009.
RESULTS: Data from 73 students were included for analysis. The most common anatomical location of abnormality causing vision loss was the cornea (n = 20, 33.9%) followed by the lens and retina (n = 11, 18.64% each). Hereditary factors (n = 29, 49.15%) and childhood diseases (n = 27, 45.76%) were the most common aetiological causes of childhood blindness. The majority (71.19%) of childhood blindness was avoidable. The present study did not demonstrate 0a significant difference in the causes of childhood blindness compared to 2009.
CONCLUSIONS: Corneal pathologies continue to represent the most common cause of vision loss amongst the surveyed population and the majority of causes of childhood blindness continue to be avoidable. These findings will facilitate the development of evidence-based targeted interventional programmes in Cambodia.
A membrane patch for improving neck wrinkles and a preparation method thereof belong to the technical field of biology. It has solved the poor problem of continuous effect of moisturizing that current neck membrane subsides exist. Film pasting: is prepared from polyvinyl alcohol 1788, folium kaki powder, sodium hyaluronate, glycerol, titanium dioxide, polyvinylpyrrolidone, sodium carboxymethylcellulose, carbomer dry powder, orchid essence and purified water. The method comprises the following steps: weighing raw materials; preparing phase A from carbomer dry powder and purified water; preparing a B phase from polyvinyl alcohol 1788, purified water, polyvinylpyrrolidone and sodium carboxymethyl cellulose; adding phase B into phase A, stirring to obtain persimmon leaf powder and sodium hyaluronate, and stirring to obtain phase C; mixing titanium dioxide, glycerol, orchid essence and purified water, adding into phase C, and stirring. The film patch for improving the neck wrinkles, prepared by the invention, can realize film forming, ventilation, long-acting moisture preservation, wrinkle removal, whitening, neck line reduction, skin microcirculation improvement and cell metabolism acceleration. The invention is suitable for improving neck wrinkles.
Currently, no effective pharmacological treatment exists for cocaine dependence. Long-term use of cocaine disrupts normal glutamate levels. If addicts stop using cocaine, glutamate levels drop, which encourages addicts to continue seeking the drug. NAC is a drug that increases intracellular cysteine levels, which in turn leads to normalization of glutamate levels. Currently, NAC is used for the treatment of cystic fibrosis, heart disease, and acetaminophen overdose. Since NAC has the capability of restoring normal glutamate levels, it holds potential as a treatment for cocaine dependence. The purpose of this study is to determine the safety and effectiveness of NAC in treating cocaine dependent individuals. In addition, this study will evaluate cocaine craving and withdrawal symptoms in individuals taking NAC.

Participants in this double-blind, placebo-controlled trial will be randomly assigned to receive either NAC or placebo. All participants will undergo an initial evaluation, which will include a physical examination, an electrocardiogram, blood samples, urine tests, and cue reactivity measures. Participants in the NAC group will receive either 600 mg or 1200 mg of NAC, two times each day for 8 weeks. In addition, all participants will receive cognitive behavioral therapy throughout the study on a weekly basis. Cocaine use will be confirmed by a urine drug screen test, three times each week. Participants will be assessed on a number of biomedical and psychosocial variables known to influence cocaine treatment outcomes. After Week 2, participants will repeat the cue reactivity procedures, which will include measuring a participant's craving response when exposed to conditioned reminders of prior cocaine use.
In visit 2, confirmed-allergic subjects will have a double-blind placebo-controlled drug challenge to a similar side chain cephalosporin, followed by a double-blind placebo-controlled challenge to a dissimilar side chain cephalosporin in visit 3. The randomization of which cephalosporin (similar or dissimilar side chain) is challenged in visits 2 and 3 differentiates the two arms.
Anesthesia induction will be performed with 2 mg/kg propofol, 1 µg/kg fentanyl and 0.6 mg/kg rocuronium as standard.After intubation, anesthesia will maintained with %40 O2 and sevoflurane at 2% volume. When the sevoflurane concentration reached 1 MAC, the fresh gas flow rate will be brought to 2 L/min. Inhalation anesthetics will be turned off 10 minutes before the end of the operation. The fresh gas flow will be increased to 6 l/min to be 100% O2. At the end of the surgery, the neuromuscular block will be antagonized with neostigmine-atropine. Sedation and agitation will be assessed immediately after extubation.
A systemic absorption study of topically applied Tolak Cream was performed in 21 patients with at least 3 actinic keratosis lesions (4 mm or greater in diameter). The steady state concentration of 5-fluorouracil in plasma was examined at 1, 2, 4, 6, 8, 10, 12, 16, and 24 hours after the last dose of a 4-week regimen in subjects with actinic keratosis after "area application" to area(s) in which actinic keratosis lesions were identified at baseline. Areas were defined as the whole region of the left cheek, right cheek, chin and forehead, bald scalp, and right and left ears, where actinic keratosis was identified at baseline. Thus, for example, if an actinic keratosis lesion was identified on the left cheek, Tolak Cream was to be applied as a thin film to the whole area of the left cheek.

Eight patients had undetectable levels of plasma 5-fluorouracil (the lower limit of quantification was 1.00 ng/ml) in all plasma samples following treatment with Tolak Cream. Among patients with detectable plasma 5-fluorouracil levels, the highest level of plasma 5-fluorouracil was generally observed at 1 hour post-dose. The mean observed maximum concentration (± standard deviation) of plasma 5-fluorouracil was 3.66 (±1.58) ng/mL with the range between 1.11 – 7.35 ng/mL. 

The catabolism of 5-fluorouracil results in inactive degradation products (such as CO2, urea, α-fluoro-β-alanine).
Community Living Center residents: Eligible Community Living Center cohort participants include all residents who reside in VA medical center-operated Community Living Centers. Members of this Community Living Center cohort include those with and without SARS-CoV-2 infection.
PROBLEM TO BE SOLVED: To obtain the above suppressant, comprising an essence of a labiate plant and capable of lightly suppressing the secretion of a adrenocortical hormone which is an index to a stress and reducing the concentration of the adrenocortical hormone in a humor. SOLUTION: This suppressant for the secretion of an adrenocortical hormone comprises an essence of a labiate plant. A lavender, a marjoram and a mint are preferred as the labiate plant. Since the secretion of the adrenocortical hormone in a saliva can effectively and safely be suppressed through the olfactory sense with an aroma, an ingredient having <200 deg.C boiling point among constituent ingredients of the plant prepared by distillation, etc., is preferably used. The objective suppressant is preferably used by a method for stimulating the olfactory sense therewith as an aroma at 0.01-10mg/m<3> concentration. When the essence is blended in a composition such as a cosmetic or a food, the amount thereof blended is preferably 0.1-30wt.% in the case of the cosmetic and 0.1-10wt.% in the case of the food or a beverage.